Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Metastatic Urothelial Cancer × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 207 Carcinoma, Non-Small-Cell Lung 199 Prostatic Neoplasms 157 Multiple Myeloma 105 Colorectal Neoplasms 96 Neoplasms 94 Squamous Cell Carcinoma of Head and Neck 87 Leukemia, Myeloid, Acute 85 Neoplasm Metastasis 80 Lung Neoplasms 80 Melanoma 74 Pancreatic Neoplasms 66 Carcinoma, Hepatocellular 63 Triple Negative Breast Neoplasms 62 Ovarian Neoplasms 61 Recurrence 59 Leukemia, Lymphocytic, Chronic, B-Cell 57 Brain Neoplasms 56 Glioblastoma 52 Lymphoma 51 Carcinoma, Renal Cell 49 Urinary Bladder Neoplasms 43 Sarcoma 43 Lymphoma, Large B-Cell, Diffuse 42 Stomach Neoplasms 41 Endometrial Neoplasms 41 Precursor Cell Lymphoblastic Leukemia-Lymphoma 40 Uterine Cervical Neoplasms 39 Head and Neck Neoplasms 39 Rectal Neoplasms 37

Interventions

zimberelimab 1 sacituzumab govitecan 1 pembrolizumab 1 enfortumab vedotin 1 avelumab 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡